Clinical Trials
Open Clinical Trials
| Full Title | A Phase I/II Trial of Induction Carboplatin/Paclitaxel with Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy with Carboplatin/ Paclitaxel, Bevacizumab and Erlotinib in Stage III A/B Non-small Cell Lung Cancer |
| Trial Type | Therapeutic |
| Disease | Lung |
| PI | Scott Gettinger |
| Primary Objective | To determine the safety and maximum tolerated dose of IPI-504 in NSCLC patients on a twice weekly schedule of administration; To recommend a dose for subsequent studies of IPI-504; To examine the pharmacokinetic parameters of IPI-504 in NSCLC patients. |
| Target Population | Patients must have pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) orStage IV NSCLC and be relapsing or refractory to prior treatment. |
| Exclusion | Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy within 4 weeks of the start of IPI-504 treatment for any biological therapy or conventional chemotherapy. |
| FDA Phase | I-II |
For further information on this clinical trial, please call the Yale Cancer Center Clinical Trials Office at 203-785-5702. | |